

Phase 4 of the International Ovarian Tumour Analysis study group: To compare the referral pattern and cost-effectiveness of using Risk of Malignancy Index (RMI) versus Logistic Regression model (LR2) to diagnose adnexal masses prior to surgery

Submission date 16/12/2012	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 04/01/2013	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 30/11/2017	Condition category Cancer	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

<http://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-comparing-different-ways-of-working-out-whether-an-ovarian-cyst-is-cancerous-iota4>

Contact information

Type(s)

Scientific

Contact name

Prof Tom Bourne

ORCID ID

<http://orcid.org/0000-0003-1421-6059>

Contact details

Early Pregnancy and Acute Gynaecology Scanning Unit
Queen Charlotte's and Chelsea Hospital
Imperial College London
Hammersmith Campus
Du Cane Road
London
United Kingdom
W12 0HS

+44 (0)20 8383 5131
t.bourne@imperial.ac.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

10/H0707/28

Study information

Scientific Title

Randomised controlled trial to compare the referral pattern and cost-effectiveness of using RMI versus LR2 to diagnose adnexal masses prior to surgery

Acronym

IOTA4

Study objectives

This comparison will show that triaging patients using logistic regression model (LR2) is likely to be superior or inferior compared to the currently standard protocol based on the Risk of Malignancy Index (RMI). This may render the preoperative management of adnexal masses.

Ethics approval required

Old ethics approval format

Ethics approval(s)

1. West London ethics committee, 09/2010, ref: 10/H0707/28
2. Imperial College London and Imperial College Healthcare NHS Trust, 9/12/2010, R&D reference number: BOUT3001

Study design

Prospective multicentre randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Diagnostic

Participant information sheet

Not available in web format, please contact a.sayasneh@imperial.ac.uk to request a patient information sheet

Health condition(s) or problem(s) studied

Ovarian cancer

Interventions

Control arm: diagnosis using the RMI

The RMI is a scoring system based on a logistic regression model to diagnose adnexal masses as benign or malignant (Jacobs et al, 1990). The RMI equals $U \times M \times CA125$, where U is the ultrasound score, M the menopausal status score, and CA125 is the level of serum CA125 in u/ml. The ultrasound score is based on five characteristics: multilocular cyst, evidence of solid areas, evidence of metastases, presence of ascites, and bilateral lesions. U equals 0 if none of these characteristics are present, 1 if one characteristic is present, and 3 if two or more characteristics are present. M equals 1 for premenopausal and 3 for postmenopausal women.

Intervention arm: diagnosis using LR2

LR2s predictors are:

1. Age of the patient (years)
2. The presence of ascites (yes=1, no=0)
3. The presence of blood flow within a papillary projection (yes=1, no=0)
4. Largest diameter of the solid component (expressed in mm but with no increase above 50 mm)
5. Irregular internal cyst walls (yes=1, no=0), and
6. The presence of acoustic shadows (yes=1, no=0). The estimated probability (risk) of malignancy equals $1/(1+e^{-z})$, where $z = 5.3718 + 0.0354(1) + 1.6159(2) + 1.1768(3) + 0.0697(4) + 0.9586(5) + 2.9486(6)$. The probability will be multiplied by 100 to yield the percentage risk.

We estimate to enroll the first patient in April 2010, the last patient in July 2012, and the last follow-up visit in July 2013.

Study visits

If surgery is necessary, the day of surgery is time zero with follow-up visits at 2 weeks, 6 weeks, and 12 months from surgery.

If surgery is not necessary, the diagnosis (i.e. the lead clinicians final decision regarding treatment) is time zero with follow-up visits 6 weeks, 4 months, and 12 months later.

Intervention Type

Other

Phase

Phase IV

Primary outcome measure

Histological diagnosis (benign or malignant) for patient who undergo surgery. Three follow up findings over one year for conservative management patients.

Secondary outcome measures

Effectiveness related variables

1. The percentage of patients with a borderline/invasive mass assigned to the moderate or high risk groups)
2. The actual safety and efficiency based on the real-life referral pattern observed in both study arms (i.e. percentage of patients with a benign mass that are conservatively managed or received local surgery, and the percentage of patients with a borderline or invasive mass that are referred to the cancer unit or cancer centre)
3. The percentage of patients with different types of surgical interventions
4. The median length of hospital stay
5. Health-related quality of life

Overall study start date

01/09/2010

Completion date

01/07/2013

Eligibility

Key inclusion criteria

1. Women (non pregnant women above the age of 16) with any abnormal morphology of the ovary evident on an ultrasound scan performed for any clinical symptom
2. Signed and dated informed consent

Participant type(s)

Patient

Age group

Adult

Sex

Female

Target number of participants

400

Key exclusion criteria

1. Premenopausal women with functional or simple cysts less the 3 cm mean diameter
2. Pregnant women

Date of first enrolment

01/09/2010

Date of final enrolment

31/05/2012

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

Queen Charlotte's and Chelsea Hospital

Early Pregnancy and Acute Gynaecology Scanning Unit

Du Cane Rd

London

United Kingdom

W12 0HS

Sponsor information

Organisation

Imperial College London and Imperial College Healthcare NHS Trust (UK)

Sponsor details

Becky Ward

Research Governance Manager

Joint Research Compliance Office

Room 5L10A

5th Floor, Lab Block

Charing Cross Hospital

Fulham Palace Road

London

England

United Kingdom

W6 8RF

+44 (0)20 3311 0205

becky.ward@imperial.ac.uk

Sponsor type

Hospital/treatment centre

Website

<http://www.imperial.ac.uk/clinicalgoveranceoffice>

ROR

<https://ror.org/041kmwe10>

Funder(s)

Funder type

Hospital/treatment centre

Funder Name

Imperial College Healthcare NHS Trust (UK)

Alternative Name(s)

Imperial NHS, imperialnhs, Imperial College Healthcare NHS Trust | London

Funding Body Type

Private sector organisation

Funding Body Subtype

Trusts, charities, foundations (both public and private)

Location

United Kingdom

Results and Publications

Publication and dissemination plan

The study has been published and disseminated as an open access publication as a PhD thesis with methods/results/discussion and conclusion

Intention to publish date**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Thesis results	Thesis available at:	01/07/2015		No	No